title: Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease.
abstract: Huntington's disease (HD) produces progressive and ultimately widespread impairment of brain function. Neostriatal atrophy alone cannot account for whole-brain losses seen postmortem, and the mutant huntingtin protein and its neuropathologic sequelae are evident throughout the brain. Whole-brain atrophy quantification encompasses the totality of mutant huntingtin's effects on brain volume and may be useful in tracking progression in trials. We studied whole-brain atrophy in HD using a 2-year follow-up design, with three annual MRI scans. We recruited 20 control subjects, 21 premanifest mutation carriers, and 40 patients with early HD and used the brain boundary shift integral to study rate and acceleration of atrophy. Among subjects with an acceptable quality 2-year scan pair, age- and gender-standardized mean brain atrophy rate was greater (P < 0.001) in the patients with HD (n = 21; 0.88%/yr; 95% confidence interval: 0.62-1.13%/yr) than that in controls (n = 13; 0.16%/yr; 0.00-0.32%/yr). In the 12 patients with early HD in whom acceleration could be directly assessed there was evidence (P= 0.048) of acceleration year-on-year (mean acceleration = 0.69% yr(-2); 95% confidence interval: 0.01% yr(-2) to 1.37% yr(-2)), although this was not formally significantly different from that in controls (n = 7, P = 0.055). Statistically significantly increased atrophy rates and acceleration were not seen overall in the premanifest group, who were on average 18 years from predicted disease onset. We conclude that the study of whole-brain atrophy has the potential to inform our understanding of the neurobiology of HD and warrants further study as one means of assessing the outcomes of future clinical trials.
authors.affiliation: Dementia Research Centre, UCL Institute of Neurology, London, United Kingdom.
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Wild
authors.forename: Susie M D
authors.initials: SM
authors.lastname: Henley
authors.forename: Nicola Z
authors.initials: NZ
authors.lastname: Hobbs
authors.forename: Chris
authors.initials: C
authors.lastname: Frost
authors.forename: David G
authors.initials: DG
authors.lastname: MacManus
authors.forename: Roger A
authors.initials: RA
authors.lastname: Barker
authors.forename: Nick C
authors.initials: NC
authors.lastname: Fox
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Tabrizi
mesh_terms: D000328:Adult; D017668:Age of Onset; D001284:Atrophy / Q000453:epidemiology / Q000473:pathology; D001921:Brain / Q000473:pathology*; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000453:epidemiology / Q000235:genetics / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D017354:Point Mutation / Q000235:genetics; D011446:Prospective Studies; D012720:Severity of Illness Index
references.citation: Neurology. 2005 May 10;64(9):1563-72
references.pmid: 15883317
references.citation: J Neurol. 2009 Feb;256(2):203-12
references.pmid: 19266143
references.citation: Clin Genet. 2004 Apr;65(4):267-77
references.pmid: 15025718
references.citation: Arch Neurol. 1993 Jan;50(1):17-9
references.pmid: 8418795
references.citation: Mov Disord. 2009 Apr 30;24(6):932-6
references.pmid: 19243073
references.citation: Neurology. 1981 Oct;31(10):1333-5
references.pmid: 6125919
references.citation: Mov Disord. 1996 Mar;11(2):136-42
references.pmid: 8684382
references.citation: Clin Sci (Lond). 2006 Jan;110(1):73-88
references.pmid: 16336206
references.citation: IEEE Trans Med Imaging. 1997 Oct;16(5):623-9
references.pmid: 9368118
references.citation: Lancet. 2004 Jan 31;363(9406):392-4
references.pmid: 15074306
references.citation: Hum Mol Genet. 1999 May;8(5):813-22
references.pmid: 10196370
references.citation: Neurology. 2005 Feb 8;64(3):548-50
references.pmid: 15699394
references.citation: J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):874-80
references.pmid: 18096682
references.citation: IEEE Trans Med Imaging. 1998 Feb;17(1):87-97
references.pmid: 9617910
references.citation: Mov Disord. 2000 May;15(3):552-60
references.pmid: 10830423
references.citation: Comput Methods Programs Biomed. 1997 May;53(1):15-25
references.pmid: 9113464
references.citation: AJNR Am J Neuroradiol. 2001 Sep;22(8):1483-9
references.pmid: 11559495
references.citation: Neurology. 2004 Jul 13;63(1):66-72
references.pmid: 15249612
references.citation: J Comput Assist Tomogr. 1998 Jan-Feb;22(1):139-52
references.pmid: 9448779
references.citation: Neurology. 2005 Sep 13;65(5):745-7
references.pmid: 16157910
references.citation: J Neurosci. 1999 Apr 1;19(7):2522-34
references.pmid: 10087066
references.citation: Expert Opin Med Diagn. 2008 Jan;2(1):47-62
references.pmid: 23485116
references.citation: Cell. 2000 Mar 31;101(1):57-66
references.pmid: 10778856
references.citation: Neuron. 1995 Nov;15(5):1193-201
references.pmid: 7576661
references.citation: Neurology. 2003 May 27;60(10):1615-20
references.pmid: 12771251
references.citation: Neurology. 2005 Jul 12;65(1):119-24
references.pmid: 16009896
references.citation: J Exp Med. 2008 Aug 4;205(8):1869-77
references.pmid: 18625748
references.citation: Lancet Neurol. 2006 Sep;5(9):724-5
references.pmid: 16914400
references.citation: Neurology. 2006 Aug 22;67(4):694-6
references.pmid: 16924028
references.citation: J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):98-100
references.pmid: 8429330